MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics - Scorecard - MDSpire

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

  • By

  • Rocío Maseda

  • María Carmen Arriba

  • Lucía Martínez-Santamaría

  • Eva Jiménez

  • Sara Herráiz-Gil

  • Nuria Illera

  • Lucía Quintana-Castanedo

  • Marta García

  • Susana Suárez-Sancho

  • Rosa Yáñez

  • Isabel Pérez-Conde

  • Marta Carretero

  • Magdalena Martínez-Queipo

  • Raquel de Paz

  • Carlos León

  • Víctor Jiménez-Yuste

  • Alberto M. Borobia

  • Ángeles Vicente

  • Su M. Lwin

  • John A. McGrath

  • María Eugenia Fernández-Santos

  • Nora Butta

  • Rosa Sacedón

  • Marcela del Río

  • Raúl de Lucas

  • María José Escámez

  • May 5, 2026

  • 0 min

Share

Clinical Scorecard: MesenSistem-EB: Systemic Haploidentical Mesenchymal Stem Cell Treatment for Recessive Dystrophic Epidermolysis Bullosa Demonstrates Clinical Improvements Linked to MCP1 and sCD40L Changes

At a Glance

CategoryDetail
Condition
Key MechanismsChronic inflammation driven by COL7A1 mutations leading to systemic inflammatory responses, impacting quality of life.
Target Population
Care Setting

Key Highlights

  • Responses correlated with changes in sCD40L and MCP1 levels, indicating potential predictive biomarkers.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor systemic inflammatory markers such as CRP, MCP1, and sCD40L, along with patient-reported outcomes over time.

      Risks

        Patient & Prescribing Data

        Children with severe RDEB.

        Three intravenous infusions of haploidentical BM-MSC (2–3×10^6 cells/kg) at 21-day intervals.

        Clinical Best Practices

        • Utilize haploidentical MSC to enhance cell tolerance and persistence, and assess immune profiles and inflammatory markers to tailor therapy based on individual patient needs.

        References

        Original Source(s)

        MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

        • by Rocío Maseda, María Carmen Arriba, Lucía Martínez-Santamaría, Eva Jiménez, Sara Herráiz-Gil, Nuria Illera, Lucía Quintana-Castanedo, Marta García, Susana Suárez-Sancho, Rosa Yáñez, Isabel Pérez-Conde, Marta Carretero, Magdalena Martínez-Queipo, Raquel de Paz, Carlos León, Víctor Jiménez-Yuste, Alberto M. Borobia, Ángeles Vicente, Su M. Lwin, John A. McGrath, María Eugenia Fernández-Santos, Nora Butta, Rosa Sacedón, Marcela del Río, Raúl de Lucas, María José Escámez

        • May 5, 2026

        Related Content

        Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

        Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

        • May 28, 2026

        PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report